Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Omalizumab is effective and safe in chronic inducible urticaria (CIndU): Real-world data from a large multi-national UCARE study.
Soegiharto R, Alizadeh Aghdam M, Sørensen JA, van Lindonk E, Bulut Demir F, Mohammad Porras N, Matsuo Y, Kiefer L, Knulst AC, Maurer M, Ritchie C, Rudenko M, Kocatürk E, Criado RFJ, Gregoriou S, Bobylev T, Kleinheinz A, Takahagi S, Hide M, Giménez-Arnau AM, Salman A, Kara RO, Dikicier BS, van Doorn MBA, Thomsen SF, van den Reek JMPA, Röckmann H. Soegiharto R, et al. Allergy. 2024 Oct 8. doi: 10.1111/all.16334. Online ahead of print. Allergy. 2024. PMID: 39377745
Multinational Drug Survival Study of Omalizumab in Patients With Chronic Urticaria and Potential Predictors for Discontinuation.
Soegiharto R, Alizadeh Aghdam M, Sørensen JA, van Lindonk E, Bulut Demir F, Porras NM, Matsuo Y, Kiefer L, Knulst AC, Maurer M, Ritchie C, Rudenko M, Kocatürk E, Criado RFJ, Gregoriou S, Bobylev T, Kleinheinz A, Takahagi S, Hide M, Giménez-Arnau AM, Salman A, Kara RO, Sevimli Dikicier B, van Doorn MBA, Thomsen SF, van den Reek JMPA, Röckmann H. Soegiharto R, et al. JAMA Dermatol. 2024 Sep 1;160(9):927-935. doi: 10.1001/jamadermatol.2024.2056. JAMA Dermatol. 2024. PMID: 39018068
Age and fast initial response predict omalizumab retreatment in chronic urticaria.
Meertens MAJ, Luijf T, van Lindonk EAM, Soegiharto R, Assil S, Alizadeh Aghdam M, Kentie PA, Knulst AC, van Doorn MBA, Röckmann H. Meertens MAJ, et al. Among authors: soegiharto r. J Allergy Clin Immunol Pract. 2023 Nov;11(11):3556-3558.e1. doi: 10.1016/j.jaip.2023.07.030. Epub 2023 Jul 28. J Allergy Clin Immunol Pract. 2023. PMID: 37517795 Free article. No abstract available.